EUCTR2019-001892-35-HU进行中（未招募）1 期
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009) - Olaparib Plus Pembrolizumab as Post-Induction Therapy in Triple Negative Breast Cancer
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc0 个研究点目标入组 317 人开始时间: 2019年10月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 317
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Have locally recurrent inoperable centrally confirmed TNBC that has not previously been treated with chemotherapy in the metastatic setting and that cannot be treated with curative intent OR Have metastatic TNBC that has not been previously treated with chemotherapy
- •2. Have been treated with anthracycline and/or a taxane in the neoadjuvant/adjuvant setting, if they received systemic treatment in the neoadjuvant/adjuvant setting, unless anthracycline and/or taxane was contraindicated or not considered the best treatment option for the participant in the opinion of the treating physician
- •3. Have measurable disease based on RECIST 1.1, as determined by local radiology review
- •4. Have provided a recently obtained or archival (no more than 3 years old) core or excisional biopsy of a tumor lesion not previously irradiated for central determination of TNBC, PD-L1, BRCA, and HRD status
- •5. Be a male or female at least 18 years of age on the day of signing the informed consent
- •6. Have an ECOG performance status of 0 or 1 as assessed within 7 days prior to the start of induction study treatment
- •7. Have a life expectancy =27 weeks from the day of first study treatment
- •8. Demonstrate adequate organ function
- •9. Must adhere to the following contraceptive use if a male participant:
- •Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- •Male participants are eligible to participate if they agree to the following during the intervention period and for at least 180 days after the last dose of study intervention:
- •Refrain from donating sperm
- •PLUS either:
- •Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
- •Must agree to use contraception unless confirmed to be azoospermic as detailed below:
- •? Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant
- •10. Must adhere to the following contraceptive use if a female participant:
- •Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- •A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •Is not a woman of childbearing potential (WOCBP)
- •Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 180 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period. The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study intervention
- •A WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention
- •- If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive
排除标准
- •INDUCTION PERIOD
- •1. Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
- •2. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
- •3. Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic treatment and is allowed
- •4. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable
- •5. Has myelodysplastic syndrome/acute myeloid leukemia or has features suggestive of MDS/AML
- •6. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- •7. Has active, or a history of, interstitial lung disease
- •8. Has a known history of active tuberculosis
- •9. Has an active infection requiring systemic therapy
- •10. Has a known history of HIV infection
- •11. Has a known history of Hepatitis B or known active Hepatitis C virus infection
- •12. Has a history of class II-IV congestive heart failure or myocardial infarction within 6 months of first study treatment
- •13. Has neuropathy =Grade 2
- •14. Has not recovered from AEs due to a previously administered therapy
- •15. Has a known history of hypersensitivity or allergy to pembrolizumab, olaparib and any of its components, and/or to any of the study chemotherapies and any of their components
- •16. Has severe hypersensitivity to the study treatments and/or any of their excipients
- •17. Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study
- •18. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the Screening Visit through 180 days after the last dose of study treatment
- •19. Is a WOCBP who has a positive urine pregnancy test within 24 hours prior to randomization or treatment allocation
- •20. Has received prior therapy with either olaparib or any other PARP inhibitor
- •21. Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
- •22. Has received colony-stimulating factors within 2 weeks prior to the first dose of study treatment
- •23. Has had an allogenic tissue/solid organ transplant
- •24. Has received previous allogenic bone marrow transplant or double umbilical cord transplantation
- •25. Had major surgery within 2 weeks of starting study intervention or has not recovered from any effects of any major surgery
- •26. Has received a live vaccine within 30 days prior to first study treatment
- •27. Is receiving any medication prohibited in combination with study chemotherapies as described in the respective product labels unless medication was stopped within 7 days prior to first study treatment
- •28. Has received prior therapy with an anti–PD-1, anti–PD-L1, or anti–PD-L2 agent or with an agent directed to another co-inhibitory T cell receptor or has previously participated in a study evaluating pembrolizumab regardless of treatment received
- •29. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dos
研究者
相似试验
进行中（未招募）
1 期
Olaparib Plus Pembrolizumab as Post-Induction Therapy in Triple Negative Breast CancerEUCTR2019-001892-35-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc317
进行中（未招募）
1 期
Olaparib Plus Pembrolizumab as Post-Induction Therapy in Triple Negative Breast Cancerocally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2019-001892-35-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc317
进行中（未招募）
1 期
Olaparib Plus Pembrolizumab as Post-Induction Therapy in Triple Negative Breast Cancerocally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2019-001892-35-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc317
进行中（未招募）
1 期
Olaparib Plus Pembrolizumab as Post-Induction Therapy in Triple Negative Breast Cancerocally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)MedDRA version: 27.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001892-35-PLMerck Sharp & Dohme LLC, a subsidiary of Merck & Co.,Inc460
进行中（未招募）
1 期
Olaparib Plus Pembrolizumab as Post-Induction Therapy in Triple Negative Breast Cancerocally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2019-001892-35-IEMerck Sharp & Dohme LLC460